Inflammatory mechanisms in HIV-associated pulmonary arterial hypertension

Seminars in Respiratory and Critical Care Medicine

Volumn 34, Issue 5, 2013, Pages 645-653

  Tcherakian, Colas ^a,b   Couderc, Louis Jean ^a,b   Humbert, Marc ^c,d,e   Godot, Véronique ^f   Sitbon, Olivier ^c,d,e   Devillier, Philippe ^b  

^a FOCH HOSPITAL   (France)

^b LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^e CENTRE CHIRURGICAL MARIE LANNELONGUE   (France)

^f UNIVERSITÉ PARIS EST CRÉTEIL   (France)

Author keywords

human immunodeficiency virus; inflammation; interleukin 6; lipopolysaccharide; pulmonary arterial hypertension

Indexed keywords

ALPHA INTERFERON; AMPHETAMINE DERIVATIVE; BETA INTERFERON; BOSENTAN; CYCLOPHOSPHAMIDE; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; INTERLEUKIN 6; METHAMPHETAMINE; MORPHINE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG USE; DYSPNEA; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; FATIGUE; FOLLOW UP; FOREIGN BODY; FRANCE; GENETIC PREDISPOSITION; GRANULOMATOSIS; HEART CATHETERIZATION; HEART OUTPUT; HEART RIGHT VENTRICLE FAILURE; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INFECTION SENSITIVITY; KNOCKOUT MOUSE; LUNG ARTERY PRESSURE; LUNG BLOOD VESSEL; MIXED CONNECTIVE TISSUE DISEASE; MIXED INFECTION; NONHUMAN; OBSERVATIONAL STUDY; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PORTOPULMONARY HYPERTENSION; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; T CELL DEPLETION; TRICUSPID VALVE REGURGITATION; VASCULAR LESION; VIRUS LOAD;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; HYPERTENSION, PULMONARY; INFLAMMATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES;

EID: 84884260498     PISSN: 10693424     EISSN: 10989048     Source Type: Journal    
DOI: 10.1055/s-0033-1356489     Document Type: Article

References (97)

1. Gottlieb M. S. Pneumocystis pneumonia-Los Angeles. 1981. Am J Public Health: 2006; 96 6 980 981, discussion 982-983
2. Kates J., Carbaugh A., Rousseau D., Jankiewicz A. Kaiser Family Foundation HIV/AIDS: the state of the epidemic after 3 decades. JAMA: 2012; 308 4 330 330
3. Stein J. H., Hsue P. Y. Inflammation, immune activation, and CVD risk in individuals with HIV infection. JAMA: 2012; 308 4 405 406
4. Freiberg M. S., Chang C. C., Kuller L. H., et al. HIV infection and the risk of acute myocardial infarction. JAMA Intern Med: 2013; 173 8 614 622
5. Almodovar S., Cicalini S., Petrosillo N., Flores S. C. Pulmonary hypertension associated with HIV infection: pulmonary vascular disease: the global perspective. Chest: 2010; 137 (6, Suppl): 6S 12S
6. Kim K. K., Factor S. M. Membranoproliferative glomerulonephritis and plexogenic pulmonary arteriopathy in a homosexual man with acquired immunodeficiency syndrome. Hum Pathol: 1987; 18 12 1293 1296
7. Proceedings of the 4th World Symposium on Pulmonary Hypertension, February 2008, Dana Point, California, USA. J Am Coll Cardiol: 2009; 54 (1, Suppl): S1 S117
8. Galiè N., Hoeper M. M., Humbert M., et al. ESC Committee for Practice Guidelines (CPG) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J: 2009; 30 20 2493 2537
9. Degano B., Guillaume M., Savale L., et al. HIV-associated pulmonary arterial hypertension: survival and prognostic factors in the modern therapeutic era. AIDS: 2010; 24 1 67 75
10. Nunes H., Humbert M., Sitbon O., et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med: 2003; 167 10 1433 1439
11. Simonneau G., Robbins I. M., Beghetti M., et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S43 S54
12. Petitpretz P., Brenot F., Azarian R., et al. Pulmonary hypertension in patients with human immunodeficiency virus infection. Comparison with primary pulmonary hypertension. Circulation: 1994; 89 6 2722 2727
13. Pellicelli A. M., Palmieri F., D'Ambrosio C., et al. Role of human immunodeficiency virus in primary pulmonary hypertension - Case reports. Angiology: 1998; 49 12 1005 1011
14. Tuder R. M., Groves B., Badesch D. B., Voelkel N. F. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol: 1994; 144 2 275 285
15. Humbert M., Sitbon O., Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med: 2004; 351 14 1425 1436
16. Humbert M., Monti G., Fartoukh M., et al. Platelet-derived growth factor expression in primary pulmonary hypertension: comparison of HIV seropositive and HIV seronegative patients. Eur Respir J: 1998; 11 3 554 559
17. Humbert M. Mediators involved in HIV-related pulmonary arterial hypertension. AIDS: 2008; 22 03 S41 S47
18. Sitbon O. HIV-related pulmonary arterial hypertension: clinical presentation and management. AIDS: 2008; 22 03 S55 S62
19. Sitbon O., Lascoux-Combe C., Delfraissy J-F., et al. Prevalence of HIV-related pulmonary arterial hypertension in the current antiretroviral therapy era. Am J Respir Crit Care Med: 2008; 177 1 108 113
20. Opravil M., Pechère M., Speich R., et al. HIV-associated primary pulmonary hypertension. A case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med: 1997; 155 3 990 995
21. Opravil M., Sereni D. Natural history of HIV-associated pulmonary arterial hypertension: trends in the HAART era. AIDS: 2008; 22 03 S35 S40
22. Humbert M., Sitbon O., Chaouat A., et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med: 2006; 173 9 1023 1030
23. Zuber J-P, Calmy A., Evison J. M., et al. Swiss HIV Cohort Study Group Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis: 2004; 38 8 1178 1185
24. Escribano-Subias P., Blanco I., López-Meseguer M., et al. REHAP investigators Survival in pulmonary hypertension in Spain: insights from the Spanish registry. Eur Respir J: 2012; 40 3 596 603
25. Hurdman J., Condliffe R., Elliot C. A., et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a Referral centre. Eur Respir J: 2012; 39 4 945 955
26. Mehta N. J., Khan I. A., Mehta R. N., Sepkowitz D. A. HIV-related pulmonary hypertension: analytic review of 131 cases. Chest: 2000; 118 4 1133 1141
27. Degano B., Yaïci A., Le Pavec J., et al. Long-term effects of bosentan in patients with HIV-associated pulmonary arterial hypertension. Eur Respir J: 2009; 33 1 92 98
28. Barbaro G., Lucchini A., Pellicelli A. M., Grisorio B., Giancaspro G., Barbarini G. Highly active antiretroviral therapy compared with HAART and bosentan in combination in patients with HIV-associated pulmonary hypertension. Heart: 2006; 92 8 1164 1166
29. Mette S. A., Palevsky H. I., Pietra G. G., et al. Primary pulmonary hypertension in association with human immunodeficiency virus infection. A possible viral etiology for some forms of hypertensive pulmonary arteriopathy. Am Rev Respir Dis: 1992; 145 5 1196 1200
30. Cool C. D., Rai P. R., Yeager M. E., et al. Expression of human herpesvirus 8 in primary pulmonary hypertension. N Engl J Med: 2003; 349 12 1113 1122
31. Valmary S., Dorfmüller P., Montani D., Humbert M., Brousset P., Degano B. Human γ-herpesviruses Epstein-Barr virus and human herpesvirus-8 are not detected in the lungs of patients with severe pulmonary arterial hypertension. Chest: 2011; 139 6 1310 1316
32. Morse J. H., Barst R. J., Itescu S., et al. Primary pulmonary hypertension in HIV infection: an outcome determined by particular HLA class II alleles. Am J Respir Crit Care Med: 1996; 153 4 Pt 1 1299 1301
33. Machado R. D., Eickelberg O., Elliott C. G., et al. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol: 2009; 54 (1, Suppl): S32 S42
34. Olivetta E., Percario Z., Fiorucci G., et al. HIV-1 Nef induces the release of inflammatory factors from human monocyte/macrophages: involvement of Nef endocytotic signals and NF-kappa B activation. J Immunol: 2003; 170 4 1716 1727
35. Percario Z., Olivetta E., Fiorucci G., et al. Human immunodeficiency virus type 1 (HIV-1) Nef activates STAT3 in primary human monocyte/macrophages through the release of soluble factors: involvement of Nef domains interacting with the cell endocytotic machinery. J Leukoc Biol: 2003; 74 5 821 832
36. Marecki J. C., Cool C. D., Parr J. E., et al. HIV-1 Nef is associated with complex pulmonary vascular lesions in SHIV-nef-infected macaques. Am J Respir Crit Care Med: 2006; 174 4 437 445
37. Plestina R., Stoner H. B. Pulmonary oedema in rats given monocrotaline pyrrole. J Pathol: 1972; 106 4 235 249
38. Voelkel N. F., Vandivier R. W., Tuder R. M. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol: 2006; 290 2 L209 L221
39. George M. P., Brower A., Kling H., et al. Pulmonary vascular lesions are common in SIV- and SHIV-env-infected macaques. AIDS Res Hum Retroviruses: 2011; 27 2 103 111
40. Ensoli B., Barillari G., Salahuddin S. Z., Gallo R. C., Wong-Staal F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature: 1990; 345 6270 84 86
41. Ascherl G., Hohenadl C., Schatz O., et al. Infection with human immunodeficiency virus-1 increases expression of vascular endothelial cell growth factor in T cells: implications for acquired immunodeficiency syndrome-associated vasculopathy. Blood: 1999; 93 12 4232 4241
42. Hofman F. M., Wright A. D., Dohadwala M. M., Wong-Staal F., Walker S. M. Exogenous tat protein activates human endothelial cells. Blood: 1993; 82 9 2774 2780
43. Liu K., Chi D. S., Li C., Hall H. K., Milhorn D. M., Krishnaswamy G. HIV-1 Tat protein-induced VCAM-1 expression in human pulmonary artery endothelial cells and its signaling. Am J Physiol Lung Cell Mol Physiol: 2005; 289 2 L252 L260
44. Matzen K., Dirkx A. EM, oudeEgbrink M. G., et al. HIV-1 Tat increases the adhesion of monocytes and T-cells to the endothelium in vitro and in vivo: implications for AIDS-associated vasculopathy. Virus Res: 2004; 104 2 145 155
45. Caldwell R. L., Lane K. B., Shepherd V. L. HIV-1 Tat interaction with cyclin T1 represses mannose receptor and the bone morphogenetic protein receptor-2 transcription. Arch Biochem Biophys: 2006; 449 1-2 27 33
46. Ehrenreich H., Rieckmann P., Sinowatz F., et al. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol: 1993; 150 10 4601 4609
47. Clouse K. A., Cosentino L. M., Weih K. A., et al. The HIV-1 gp120 envelope protein has the intrinsic capacity to stimulate monokine secretion. J Immunol: 1991; 147 9 2892 2901
48. Dornadula G., Zhang H., VanUitert B., et al. Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA: 1999; 282 17 1627 1632
49. Schrager L. K., D'Souza M. P. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA: 1998; 280 1 67 71
50. Speich R., Jenni R., Opravil M., Jaccard R. Regression of HIV-associated pulmonary arterial hypertension and long-term survival during antiretroviral therapy. Swiss Med Wkly: 2001; 131 45-46 663 665
51. Barnier A., Frachon I., Dewilde J., Gut-Gobert C., Jobic Y., Leroyer C. Improvement of HIV-related pulmonary hypertension after the introduction of an antiretroviral therapy. Eur Respir J: 2009; 34 1 277 278
52. Tcherakian C., Rivaud E., Zucman D., Metivier A-C, Couderc L-J. Curing HIV-associated pulmonary arterial hypertension. Eur Respir J: 2012; 39 4 1045 1046
53. Furuya Y., Satoh T., Kuwana M. Interleukin-6 as a potential therapeutic target for pulmonary arterial hypertension. Int J Rheumatol: 2010; 2010 720305
54. Montani D., Achouh L., Marcelin A. G., et al. Reversibility of pulmonary arterial hypertension in HIV/HHV8-associated Castleman's disease. Eur Respir J: 2005; 26 5 969 972
55. Jais X., Launay D., Yaici A., et al. Immunosuppressive therapy in lupus- and mixed connective tissue disease-associated pulmonary arterial hypertension: a retrospective analysis of twenty-three cases. Arthritis Rheum: 2008; 58 2 521 531
56. Voelkel N. F., Gomez-Arroyo J., Mizuno S. COPD/emphysema: the vascular story. Pulm Circ: 2011; 1 3 320 326
57. Dib H., Tamby M. C., Bussone G., et al. Targets of anti-endothelial cell antibodies in pulmonary hypertension and scleroderma. Eur Respir J: 2012; 39 6 1405 1414
58. Subramanian S., Tawakol A., Burdo T. H., et al. Arterial inflammation in patients with HIV. JAMA: 2012; 308 4 379 386
59. Kuller L. H., Tracy R., Belloso W., et al. INSIGHT SMART Study Group Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med: 2008; 5 10 e203
60. Rodger A. J., Fox Z., Lundgren J. D., et al. INSIGHT Strategies for Management of Antiretroviral Therapy (SMART) Study Group Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis: 2009; 200 6 973 983
61. Soon E., Holmes A. M., Treacy C. M., et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation: 2010; 122 9 920 927
62. Karavolias G. K., Georgiadou P., Gkouziouta A., et al. Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses. Expert Opin Ther Targets: 2010; 14 12 1283 1289
63. Selimovic N., Bergh C-H, Andersson B., Sakiniene E., Carlsten H., Rundqvist B. Growth factors and interleukin-6 across the lung circulation in pulmonary hypertension. Eur Respir J: 2009; 34 3 662 668
64. Humbert M., Monti G., Brenot F., et al. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med: 1995; 151 5 1628 1631
65. Price L. C., Montani D., Tcherakian C., et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats. Eur Respir J: 2011; 37 4 813 822
66. Steiner M. K., Syrkina O. L., Kolliputi N., Mark E. J., Hales C. A., Waxman A. B. Interleukin-6 overexpression induces pulmonary hypertension. Circ Res: 2009; 104 2 236 244, 28p, 244
67. Savale L., Tu L., Rideau D., et al. Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res: 2009; 10 6
68. Pendergrass S. A., Hayes E., Farina G., et al. Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS ONE: 2010; 5 8 e12106
69. Price L. C., Wort S. J., Perros F., et al. Inflammation in pulmonary arterial hypertension. Chest: 2012; 141 1 210 221
70. Tcherakian C., Rivaud E., Catherinot E., Zucman D., Metivier A-C, Couderc L-J. [Pulmonary arterial hypertension related to HIV: is inflammation related to IL-6 the cornerstone?]. Rev Pneumol Clin: 2011; 67 4 250 257
71. Leeansyah E., Malone D. FG, Anthony D. D., Sandberg J. K. Soluble biomarkers of HIV transmission, disease progression and comorbidities. Curr Opin HIV AIDS: 2013; 8 2 117 124
72. Baker J. V., Neuhaus J., Duprez D., et al. INSIGHT SMART Study Group Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr: 2011; 56 1 36 43
73. Marchetti G., Cozzi-Lepri A., Merlini E., et al. ICONA Foundation Study Group Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. AIDS: 2011; 25 11 1385 1394
74. Nixon D. E., Landay A. L. Biomarkers of immune dysfunction in HIV. Curr Opin HIV AIDS: 2010; 5 6 498 503
75. Giaid A., Yanagisawa M., Langleben D., et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med: 1993; 328 24 1732 1739
76. McMillen M. A., Huribal M., Cunningham M. E., Kumar R., Sumpio B. E. Endothelin-1 increases intracellular calcium in human monocytes and causes production of interleukin-6. Crit Care Med: 1995; 23 1 34 40
77. Huribal M., Kumar R., Cunningham M. E., Sumpio B. E., McMillen M. A. Endothelin-stimulated monocyte supernatants enhance neutrophil superoxide production. Shock: 1994; 1 3 184 187
78. Cunningham M. E., Huribal M., Bala R. J., McMillen M. A. Endothelin-1 and endothelin-4 stimulate monocyte production of cytokines. Crit Care Med: 1997; 25 6 958 964
79. Ehrenreich H., Anderson R. W., Fox C. H., et al. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J Exp Med: 1990; 172 6 1741 1748
80. Lacasse C., Turcotte S., Gingras D., Rola-Pleszczynski M. Adhesion-independent synergy of monocytes and endothelial cells in cytokine production: regulation of IL-6 and GM-CSF production by PAF. Mediators Inflamm: 1996; 5 1 56 61
81. Brenchley J. M., Schacker T. W., Ruff L. E., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med: 2004; 200 6 749 759
82. Brenchley J. M., Price D. A., Schacker T. W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med: 2006; 12 12 1365 1371
83. Ciccone E. J., Read S. W., Mannon P. J., et al. Cycling of gut mucosal CD4+ T cells decreases after prolonged anti-retroviral therapy and is associated with plasma LPS levels. Mucosal Immunol: 2010; 3 2 172 181
84. Jiang W., Lederman M. M., Hunt P., et al. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis: 2009; 199 8 1177 1185
85. Mehandru S., Poles M. A., Tenner-Racz K., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med: 2004; 200 6 761 770
86. Sugiura M., Inagami T., Kon V. Endotoxin stimulates endothelin-release in vivo and in vitro as determined by radioimmunoassay. Biochem Biophys Res Commun: 1989; 161 3 1220 1227
87. Loppnow H., Libby P. Adult human vascular endothelial cells express the IL6 gene differentially in response to LPS or IL1. Cell Immunol: 1989; 122 2 493 503
88. Jirik F. R., Podor T. J., Hirano T., et al. Bacterial lipopolysaccharide and inflammatory mediators augment IL-6 secretion by human endothelial cells. J Immunol: 1989; 142 1 144 147
89. Haziot A., Rong G. W., Silver J., Goyert S. M. Recombinant soluble CD14 mediates the activation of endothelial cells by lipopolysaccharide. J Immunol: 1993; 151 3 1500 1507
90. von Asmuth E. J., Dentener M. A., Bazil V., Bouma M. G., Leeuwenberg J. F., Buurman W. A. Anti-CD14 antibodies reduce responses of cultured human endothelial cells to endotoxin. Immunology: 1993; 80 1 78 83
91. Dentener M. A., Bazil V., Von Asmuth E. J., Ceska M., Buurman W. A. Involvement of CD14 in lipopolysaccharide-induced tumor necrosis factor-alpha, IL-6 and IL-8 release by human monocytes and alveolar macrophages. J Immunol: 1993; 150 7 2885 2891
92. Shao D., Park J. ES, Wort S. J. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol Res: 2011; 63 6 504 511
93. Chege D., Sheth P. M., Kain T., et al. Toronto Mucosal Immunology Group Sigmoid Th17 populations, the HIV latent reservoir, and microbial translocation in men on long-term antiretroviral therapy. AIDS: 2011; 25 6 741 749
94. Sheth P. M., Chege D., Shin L. YY., et al. Immune reconstitution in the sigmoid colon after long-term HIV therapy. Mucosal Immunol: 2008; 1 5 382 388
95. George P. M., Cunningham M. E., Galloway-Phillipps N., et al. Endothelin-1 as a mediator and potential biomarker for interferon induced pulmonary toxicity. Pulm Circ: 2012; 2 4 501 504
96. Spikes L., Dalvi P., Tawfik O., et al. Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine. Am J Respir Crit Care Med: 2012; 185 11 1235 1243
97. George M. P., Champion H. C., Gladwin M. T., Norris K. A., Morris A. Injection drug use as a "second hito" in the pathogenesis of HIV-associated pulmonary hypertension. Am J Respir Crit Care Med: 2012; 185 11 1144 1146